Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 7/20 | 0.40 |
| ▸ | TNKS | O95271 | 3/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5895177 | 0.82 | TACR1 (0.46) | TSHRALOX15TACR1PARP1TNKS | |
| SCHEMBL5896006 | 0.78 | TACR1 (0.42) | TSHRALOX15TACR1PARP1TNKS | |
| SCHEMBL5763660 | 0.70 | HTT (0.58) | GPR119 | |
| SCHEMBL5894893 | 0.67 | TACR1 (0.46) | TSHRALOX15TACR1OPRD1OPRK1 | |
| SCHEMBL29383287 | 0.66 | CCR5 (0.42) | TACR1PARP1TNKSTNKS2OPRD1 | |
| SCHEMBL23849296 | 0.65 | TSHR (0.51) | TSHRALOX15TACR1OPRD1OPRK1 | |
| SCHEMBL17886659 | 0.65 | TACR1 (0.61) | TSHRALOX15TACR1OPRD1OPRK1 | |
| SCHEMBL14314354 | 0.64 | OPRD1 (0.49) | TSHRALOX15OPRD1OPRK1GPR119 | |
| SCHEMBL29857484 | 0.64 | ACACB (0.40) | TACR1PARP1TNKSTNKS2OPRD1 | |
| SCHEMBL23247227 | 0.64 | ACACB (0.40) | TACR1PARP1TNKSTNKS2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | TSHR 1067/4885ALOX15 2537/4885TACR1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.